Posts on ‘October 2nd, 2009’

NEW YORK, Oct. 2 (HSMN NewsFeed) — Delcath Systems, Inc. (Nasdaq: DCTH ), a clinical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that it appointed Krishna Kandarpa, MD, PhD, its E…
Devices, Oncology, Personnel
Delcath Systems

Largest Hospital in New England Orders Four Treatment Systems STOCKHOLM, Oct., 2–(HSMN NewsFeed)–Massachusetts General Hospital (MGH) Cancer Center has purchased four radiation therapy treatment systems from Elekta (STO:EKTAB), including 3 Elekta …
Devices, Oncology
Elekta, Elekta Infinity, Elekta Synergy, VMAT, IMRT, radiotherapy

HOUSTON, Oct. TWO (HSMN NewsFeed) — Cyberonics, Inc. (Nasdaq: CYBX ) today announced two collaborations in the field of EEG-based seizure detection to build on its job as the leader in clinical devices for epilepsy. On October 1, 2009, Cyberonics e…
Devices, Neurology
Cyberonics, NeuroVista, Vagus Nerve Stimulation, epilepsy

RSIPPANY, NJ - (HSMN NewsFeed) - The Medicines Company (NASDAQ:MDCO ) today announced the resignation of John P. Kelley as the Company’s President and Chief Operating Officer. On September 29, 2009, John P. Kelley resigned as President and Chief Operati…
Biopharmaceuticals, Personnel
The Medicines Company

DETROIT, Oct. 2 (HSMN NewsFeed) — Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) announced that, as part of the previously announced settlement of the legal proceedings related to Lexapro(R) (escitalopram oxalate) tablets, it closed an Asset …
Biopharmaceuticals, Litigation, Licensing
Caraco Medical, Forest Laboratories, Lexapro, escitalopram